|
PF-219,061
PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It did not advance into clinical trials. See also * ABT-670 * ABT-724 * Cabergoline * Bremelanotide * Flibanserin * Intrinsa * Melanotan II * OSU-6162 * PF-592,379 PF-592,379 is a drug developed by Pfizer which acts as a potent, functional_selectivity, selective and orally active agonist for the dopamine D3_receptor, D3 Receptor (biochemistry), receptor, which was under development as a potential medication ... * Pramipexole * Tibolone * UK-414,495 References {{Dopaminergics Dopamine agonists Female sexual dysfunction drugs Phenylmorpholines 3-Hydroxyphenyl compounds Drugs developed by Pfizer Abandoned drugs Aphrodisiacs ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Phenylmorpholines
Substituted phenylmorpholines, or substituted phenmetrazines alternatively, are chemical derivatives of 2-phenylmorpholine or of the psychostimulant drug phenmetrazine. Most such compounds act as Monoamine releasing agent, releasers of monoamine neurotransmitters, and have stimulant effects. Some also act as agonists at serotonin receptors, and compounds with an N-propyl substitution act as dopamine receptor agonists. A number of derivatives from this class have been investigated for medical applications, such as for use as anorectics or medications for the treatment of ADHD. Some compounds have also become subject to illicit use as designer drugs. List of phenylmorpholines Additional phenylmorpholines and their activities as monoamine releasing agents (MRAs) have been described. See also * Substituted amphetamine * Substituted benzofuran * Substituted cathinone * Substituted methylenedioxyphenethylamine * List of aminorex analogues * List of methylphenidate analogues * Li ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
OSU-6162
OSU-6162 (PNU-96391) is a compound which acts as a partial agonist at both dopamine D2 receptors and 5-HT2A receptors. It acts as a dopamine stabilizer in a similar manner to the closely related drug pridopidine, and has antipsychotic, anti- addictive and anti-Parkinsonian effects in animal studies. Both enantiomers show similar activity but with different ratios of effects, with the (S) enantiomer (–)-OSU-6162 that is more commonly used in research, having higher binding affinity to D2 but is a weaker partial agonist at 5-HT2A, while the (R) enantiomer (+)-OSU-6162 has higher efficacy at 5-HT2A but lower D2 affinity. See also * Flumexadol * LPH-5 * PF-219,061 PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction. It d ... References {{Serotonergics Benzosulfones Dopamine agon ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
D3 Receptor
Dopamine receptor D3 is a protein that in humans is encoded by the ''DRD3'' gene. This gene encodes the D3 subtype of the dopamine receptor. The D3 subtype inhibits adenylyl cyclase through inhibitory G-proteins. This receptor is expressed in phylogenetically older regions of the brain, suggesting that this receptor plays a role in cognitive and emotional functions. It is a target for drugs which treat schizophrenia, drug addiction, and Parkinson's disease. Alternative splicing of this gene results in multiple transcript variants that would encode different isoforms, although some variants may be subject to nonsense-mediated decay (NMD). On a side note, it is also the Dopamine Receptor sub-type possessing the highest binding affinity for Dopamine itself and may explain why non-ergoline Dopamine agonist, Dopamine Agonists are D3-preferring Function Alpha-synuclein (α-Syn) aggregation via Lewy bodies inclusion, a pathogenic signature exclusively present in PD patients, is decr ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ABT-670
ABT-670 is a drug which acts as a potent, orally bioavailable dopamine agonist selective for the D4 subtype, which was developed as a possible treatment for erectile dysfunction, although its current uses are limited to scientific research. See also * ABT-724 * Bremelanotide * Cabergoline * Flibanserin * Intrinsa * Melanotan II * Pramipexole * PF-219,061 * Tibolone * UK-414,495 UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The c ... References Dopamine agonists Piperidines Amine oxides Pyridinium compounds {{genito-urinary-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
ABT-724
ABT-724 is a drug which acts as a dopamine agonist, and is selective for the D4 subtype. It was developed as a possible drug for the treatment of erectile dysfunction, although poor oral bioavailability means alternative drugs such as ABT-670 may be more likely to be developed commercially. Nonetheless, it continues to be used in scientific research into the function of the D4 receptor. See also * ABT-670 * Bremelanotide * Cabergoline * Flibanserin * Intrinsa * Melanotan II * Pramipexole * PF-219,061 * Tibolone * UK-414,495 UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The c ... References Dopamine agonists Piperazines 2-Pyridyl compounds Benzimidazoles {{genito-urinary-drug-stub ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
UK-414,495
UK-414,495 is a drug developed by Pfizer for the treatment of female sexual arousal disorder. UK-414,495 acts as a potent, selective inhibitor of the enzyme neutral endopeptidase, which normally serves to break down the neuropeptide VIP. The consequent increase in VIP activity alters blood flow to the genital region leading to increased lubrication and muscle relaxation. See also * ABT-670 * ABT-724 * Bremelanotide * Cabergoline * Flibanserin * Testosterone (patch) * Melanotan II * Pramipexole Pramipexole, sold under the brand Mirapex among others, is a medication used to treat Parkinson's disease and restless legs syndrome. In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a ... * PF-219,061 * S-17092 * Tibolone References Hydrolase inhibitors Female sexual dysfunction drugs Thiadiazoles Carboxamides Carboxylic acids Aphrodisiacs Cyclopentanes Drugs developed by Pfizer {{genito-urinary-d ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
PF-592,379
PF-592,379 is a drug developed by Pfizer which acts as a potent, functional_selectivity, selective and orally active agonist for the dopamine D3_receptor, D3 Receptor (biochemistry), receptor, which was under development as a potential medication for the treatment of female sexual dysfunction and male erectile dysfunction. Unlike some other less selective D3 agonists, a research study showed that PF-592,379 has little abuse potential in animal studies, and so was selected for further development and potentially human clinical trials. drug development, Development has since been discontinued. See also * 7-OH-DPAT * PD-128,907 * PF-219,061 References {{Dopaminergics Dopamine agonists Female sexual dysfunction drugs Morpholines Drugs developed by Pfizer Abandoned drugs Disubstituted pyridines Aphrodisiacs ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Drug Development
Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process—from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials—to approved vaccine or drug typically takes more than a decade. New chemical entity development Broadly, the process of drug development can be divided into preclinical and clinical work. Pre-clinical New chemical entities (NCEs, also known as new molecular entities or NMEs) are compounds that emerge from the process of drug discovery. These h ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Drugs Developed By Pfizer
A drug is any chemical substance other than a nutrient or an essential dietary ingredient, which, when administered to a living organism, produces a biological effect. Consumption of drugs can be via inhalation, injection, smoking, ingestion, absorption via a patch on the skin, suppository, or dissolution under the tongue. In pharmacology, a drug is a chemical substance, typically of known structure, which, when administered to a living organism, produces a biological effect. A pharmaceutical drug, also called a medication or medicine, is a chemical substance used to treat, cure, prevent, or diagnose a disease or to promote well-being. Traditionally drugs were obtained through extraction from medicinal plants, but more recently also by organic synthesis. Pharmaceutical drugs may be used for a limited duration, or on a regular basis for chronic disorders. Classification Pharmaceutical drugs are often classified into drug classes—groups of related drugs that have sim ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Female Sexual Dysfunction Drugs
An organism's sex is female (symbol: ♀) if it produces the ovum (egg cell), the type of gamete (sex cell) that fuses with the male gamete (sperm cell) during sexual reproduction. A female has larger gametes than a male. Females and males are results of the anisogamous reproduction system, wherein gametes are of different sizes (unlike isogamy where they are the same size). The exact mechanism of female gamete evolution remains unknown. In species that have males and females, sex-determination may be based on either sex chromosomes, or environmental conditions. Most female mammals, including female humans, have two X chromosomes. Characteristics of organisms with a female sex vary between different species, having different female reproductive systems, with some species showing characteristics secondary to the reproductive system, as with mammary glands in mammals. In humans, the word ''female'' can also be used to refer to gender in the social sense of gender role or g ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Dopamine Agonists
A dopamine agonist is a compound that activates dopamine receptors. There are two families of dopamine receptors, D1-like and D2-like. They are all G protein-coupled receptors. D1- and D5-receptors belong to the D1-like family and the D2-like family includes D2, D3 and D4 receptors. Dopamine agonists are primarily used in the treatment of the motor symptoms of Parkinson's disease, and to a lesser extent, in hyperprolactinemia and restless legs syndrome. They are also used off-label in the treatment of clinical depression. Impulse control disorders are associated with the use of dopamine agonists. Medical uses Parkinson's disease Dopamine agonists are mainly used in the treatment of Parkinson's disease. The cause of Parkinson's is not fully known but genetic factors, for example specific genetic mutations, and environmental triggers have been linked to the disease. In Parkinson's disease dopaminergic neurons that produce the neurotransmitter dopamine in the brain slowly br ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
